Peptide News
A static news aggregator refreshed from FDA MedWatch, PubMed, and ClinicalTrials.gov so the site can surface real signal without inventing headlines.
Latest sync: Nov 21, 2026, 12:27 PM. This page favors official and public primary sources over generic news scraping.
Display order is chronological from newest to oldest; future-dated or recently indexed items are pushed to the end.
Status: live
Status: live
Status: live
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Commun Mass Spectrom • Retatrutide • Journal Article
What moved most recently
Newly surfaced trials, FDA action, and PubMed additions sorted with the newest items first.
Newest peptide and GLP-1 updates
A rolling stream of the most recent official and public-source items in the tracker. Future-dated PubMed indexing artifacts stay at the bottom.
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.
Rapid Commun Mass Spectrom • Retatrutide • Journal Article
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Sterile Products Due to Lack of Sterility Assurance
FOR IMMEDIATE RELEASE - Tomball, Texas – November 20, 2026 – Greenwich Rx, a 503A compounding pharmacy, is voluntarily recalling specific lots of compounded sterile products that remain within their beyond-use dates to the consumer level, including some products that were compounded by Greenwich Rx
Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity
RECRUITING • University Medical Centre Ljubljana
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
COMPLETED • Eli Lilly and Company
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
NOT_YET_RECRUITING • University of Minnesota
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
ACTIVE_NOT_RECRUITING • Novartis
Semaglutide in Alcohol Use Disorder
NOT_YET_RECRUITING • University of Minnesota
Popularity Without Proof: A Narrative Review of Peptide Adjuncts to Testosterone Therapy in Body Composition and Functional-Driven Use.
Am J Mens Health • BPC-157 • Journal Article
Chatbots and Social Media-Embedded AI Assistants Provide Inconsistent Information on the Use of Unregulated Peptides Marketed for Musculoskeletal Recovery.
HSS J • BPC-157 • Journal Article
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE_NOT_RECRUITING • Eli Lilly and Company
New-onset depersonalization-derealization syndrome following semaglutide therapy.
JCEM Case Rep • Semaglutide • Case Reports
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
RECRUITING • Hudson Biotech
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease
RECRUITING • Hudson Biotech
Detecting GHRH Analogue Tesamorelin and Its Metabolites in Post-Administration Human Urine and Serum Using LC-HRMS/MS.
Drug Test Anal • Tesamorelin • Journal Article
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ACTIVE_NOT_RECRUITING • Eli Lilly and Company
GLP-1 based therapy of obesity and type 2 diabetes.
Diabetol Int • Tirzepatide • Journal Article
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
RECRUITING • Johns Hopkins University
Weight management in people with HIV.
Lancet HIV • Tesamorelin • Journal Article
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.
Diabetol Int • Tirzepatide • Journal Article
The GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats.
Neuropharmacology • Semaglutide • Journal Article
Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
SWEDESBORO, N.J., (October 21, 2026) - Wedgewood Pharmacy LLC ("Wedgewood") is recalling certain compounded veterinary medications within expiry at the provider/customer level due to inconsistencies in the reliability of certain analytical testing data generated by their laboratory, potentially resu
Innovative Treatments for Obstructive Sleep Apnea.
Neurol Clin • Tirzepatide • Journal Article
GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.
Int J Cardiol • Tirzepatide • Journal Article
The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
J Diabetes Metab Disord • Retatrutide • Journal Article
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING • Massachusetts General Hospital
FDA.gov
Regulatory and enforcement signal from FDA feeds that touch peptides, GLP-1s, compounding, and obesity.
ClinicalTrials.gov
Recently updated or newly visible clinical studies tied to tracked compounds and obesity-adjacent programs.
PubMed
Recent research hits for tracked peptide and GLP-1 terms, with reviews and meta-analyses surfaced when available.
This page is built from a generated JSON snapshot refreshed by scheduled syncs, not from a live browser request. FDA items come from RSS feeds, PubMed items come from NCBI utilities, and study updates come from the ClinicalTrials.gov API. The page is date-ordered for readability, while the underlying generator still scores relevance for homepage surfacing and future editorial modules.